Literature DB >> 10551675

Abnormalities of adhesion molecules and chemokines in scleroderma.

S Sato1.   

Abstract

Early lesions of systemic sclerosis (SSc) consist of altered endothelial cells (EC) function, perivascular infiltrating monocytes, and activated T cells adjacent to activated fibroblasts. The interactions among leukocytes, EC, and fibroblasts depend on expression and function of cell adhesion molecules and chemokines. The release of soluble cell adhesion molecules expressed on EC may represent the ongoing EC activation that correlates with some complications and early stages of SSc. Recently, chemokine abnormalities have been described in SSc, which might explain the altered accumulation of some leukocyte subsets in the affected tissues. Aberrant interactions between leukocytes and fibroblasts have also been reported. Thus, recent studies indicate that many steps of cell-cell interactions become dysregulated in SSc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551675

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  16 in total

1.  Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis.

Authors:  Y Shimada; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Cyclophosphamide responsive interstitial lung disease in "overlap syndrome": a clinical pathology conference held by the division of rheumatology at the hospital for special surgery.

Authors:  Elizabeth Schulman; Kun Chen; Gregory Saboeiro; Abraham Sanders; Kyriakos Kirou; Robert F Spiera; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2010-10-26

3.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

4.  T cell repertoire in patients with stable scleroderma.

Authors:  K P Tiev; J Abriol; M C Burland; D Antonelli; D Klatzmann; J Cabane; O Boyer
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

5.  Alpha4beta1 and alpha4beta7 CD4 T cell numbers increase and CLA CD4 T cell numbers decrease in systemic sclerosis.

Authors:  E Scala; R Paganelli; F Sampogna; D Abeni; L Colonna; O De Pità; P Puddu; G Russo
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.

Authors:  M Hasegawa; S Sato; T Echigo; Y Hamaguchi; M Yasui; K Takehara
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

7.  Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  K Yanaba; K Takehara; S Sato
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

8.  Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis.

Authors:  J-Y Kim; S-K Kwok; K-H Hur; H-J Kim; N S Kim; S-A Yoo; W-U Kim; C-S Cho
Journal:  Clin Exp Immunol       Date:  2008-03-18       Impact factor: 4.330

9.  The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.

Authors:  Bradley J Rabquer; Yong Hou; Francesco Del Galdo; G Kenneth Haines; Michele L Gerber; Sergio A Jimenez; James R Seibold; Alisa E Koch
Journal:  Rheumatology (Oxford)       Date:  2009-05-13       Impact factor: 7.580

10.  Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion.

Authors:  Y Hou; B J Rabquer; M L Gerber; F Del Galdo; S A Jimenez; G K Haines; W G Barr; M C Massa; J R Seibold; A E Koch
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.